Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

15.08
-0.1100-0.72%
Post-market: 15.100.0200+0.13%18:08 EDT
Volume:574.15K
Turnover:8.66M
Market Cap:776.51M
PE:7.32
High:15.25
Open:15.09
Low:14.86
Close:15.19
52wk High:21.03
52wk Low:7.90
Shares:51.49M
Float Shares:21.84M
Volume Ratio:0.73
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.06
EPS(LYR):2.06
ROE:44.85%
ROA:-0.54%
PB:2.62
PE(LYR):7.32

Loading ...

Theravance Biopharma Is Maintained at Hold by TD Cowen

Dow Jones
·
Mar 23

Theravance Biopharma price target raised to $15 from $13 at TD Cowen

TIPRANKS
·
Mar 23

Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance

TIPRANKS
·
Mar 23

Theravance Biopharma Price Target Maintained With a $21.00/Share by BTIG

Dow Jones
·
Mar 20

Theravance Biopharma investors face litigation after 26% stock plunge

Reuters
·
Mar 19

Ireland's Theravance Biopharma Q4 revenue misses expectations

Reuters
·
Mar 19

Theravance Biopharma Q4 Operating Income USD 20.012 Million

Reuters
·
Mar 19

Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate

Benzinga
·
Mar 19

Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10

TIPRANKS
·
Mar 19

Theravance Biopharma Q4 EPS USD 1.15

THOMSON REUTERS
·
Mar 19

Corrected-Theravance Biopharma Q4 Revenue USD 45.9 Million VS. Ibes Estimate USD 58.5 Million (Corrects Amount)

THOMSON REUTERS
·
Mar 19

Theravance Biopharma Q4 Adjusted Net Income USD 3.131 Million VS. Ibes Estimate USD 58.3 Million

THOMSON REUTERS
·
Mar 19

Corrected-Theravance Biopharma Q4 Adjusted Net Income USD 3.131 Million (Removes Reference to Estimate)

THOMSON REUTERS
·
Mar 19

Theravance Biopharma SVP, Comm & Medical Affairs Rhonda Farnum disposes of USD 432,167 in common shares

Reuters
·
Mar 19

Theravance Biopharma options imply 3.2% move in share price post-earnings

TIPRANKS
·
Mar 06

Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss

TIPRANKS
·
Mar 05

B. Riley Downgrades Theravance Biopharma to Neutral From Buy, Adjusts Price Target to $14 From $28

MT Newswires Live
·
Mar 04

Theravance Biopharma Inc : Btig Cuts Target Price to $21 From $40

THOMSON REUTERS
·
Mar 04

Theravance Biopharma Down Nearly 27%, On Pace for Largest Percent Decrease Since August 2021 -- Data Talk

Dow Jones
·
Mar 04

Top Midday Decliners

MT Newswires Live
·
Mar 04